CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myelomaCARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 studyCash and cash equivalents, deposits and short-term investments of$1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into ...